Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
复制标题
DOI：
10.7326/0003-4819-159-1-201307020-00003
复制
发表时间：
2013-07-02
影响因子：
39.2
通讯作者：
Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team
中科院分区：
文献类型：
--
作者：
Goldfine AB;Fonseca V;Jablonski KA;Chen YD;Tipton L;Staten MA;Shoelson SE;Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team
短期研究表明，双水杨酯可改善2型糖尿病（T2DM）患者的血糖。
评估双水杨酯治疗T2DM 1年的有效性和安全性。
安慰剂对照、平行试验；计算机随机分组和集中分配，患者、医护人员和研究人员对分组不知情。（ClinicalTrials.gov：NCT00799643）
美国的3家私人诊所和18个学术中心。
年龄在18 - 75岁之间、空腹血糖水平为12.5 mmol/L或更低（≤225 mg/dL）且糖化血红蛋白（HbA1c）水平在7.0% - 9.5%之间的糖尿病患者。
286名参与者（在2009年1月至2011年7月之间）被随机分配接受48周的安慰剂（n = 140）或双水杨酯3.5 g/d（n = 146）治疗，同时继续当前的治疗，对283名参与者进行了分析（安慰剂组n = 137；双水杨酯组n = 146）。
糖化血红蛋白水平的变化（主要结局）以及安全性和有效性指标。
双水杨酯组48周内的平均HbA1c水平比安慰剂组低0.37%（95%置信区间，−0.53%至−0.21%；P < 0.001）。尽管双水杨酯组患者同时使用的糖尿病药物减量幅度大于安慰剂组，但血糖仍得到改善。循环白细胞、中性粒细胞和淋巴细胞计数降低表明双水杨酯具有抗炎作用。双水杨酯组脂联素和血细胞比容水平升高幅度更大，空腹血糖、尿酸和甘油三酯水平降低，但体重和低密度脂蛋白胆固醇水平也升高。尿白蛋白水平升高，但停药后可逆转；估算的肾小球滤过率无变化。
试验持续时间和研究的患者数量不足以确定双水杨酯在T2DM中的长期风险 - 获益情况。
双水杨酯可改善T2DM患者的血糖并降低炎症介质。有必要继续评估混合的心肾相关指标。
美国国立卫生研究院
Short-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM). To assess 1-year efficacy and safety of salsalate in T2DM. Placebo-controlled, parallel trial; computerized randomization and centralized allocation, with patients, providers, and researchers blinded to assignment. (ClinicalTrials.gov: NCT00799643) 3 private practices and 18 academic centers in the United States. Persons aged 18 to 75 years with fasting glucose levels of 12.5 mmol/L or less (≤225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were treated for diabetes. 286 participants were randomly assigned (between January 2009 and July 2011) to 48 weeks of placebo (n = 140) or salsalate, 3.5 g/d (n = 146), in addition to current therapies, and 283 participants were analyzed (placebo, n = 137; salsalate, n = 146). Change in hemoglobin A1c level (primary outcome) and safety and efficacy measures. The mean HbA1c level over 48 weeks was 0.37% lower in the salsalate group than in the placebo group (95% CI, −0.53% to −0.21%; P < 0.001). Glycemia improved despite more reductions in concomitant diabetes medications in salsalate recipients than in placebo recipients. Lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of salsalate. Adiponectin and hematocrit levels increased more and fasting glucose, uric acid, and triglyceride levels decreased with salsalate, but weight and low-density lipoprotein cholesterol levels also increased. Urinary albumin levels increased but reversed on discontinuation; estimated glomerular filtration rates were unchanged. Trial duration and number of patients studied were insufficient to determine long-term risk–benefit of salsalate in T2DM. Salsalate improves glycemia in patients with T2DM and decreases inflammatory mediators. Continued evaluation of mixed cardiorenal signals is warranted. National Institutes of Health.
登录
查看更多内容
影响因子：
56.9
作者：
JURIVICH, DA;SISTONEN, L;MORIMOTO, RI
通讯作者：
MORIMOTO, RI
影响因子：
56.9
作者：
KOPP, E;GHOSH, S
通讯作者：
GHOSH, S
DOI：
10.1126/science.1215327
发表时间：
2012-05-18
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Hawley SA;Fullerton MD;Ross FA;Schertzer JD;Chevtzoff C;Walker KJ;Peggie MW;Zibrova D;Green KA;Mustard KJ;Kemp BE;Sakamoto K;Steinberg GR;Hardie DG
通讯作者：
Hardie DG
影响因子：
39.2
作者：
Goldfine AB;Fonseca V;Jablonski KA;Pyle L;Staten MA;Shoelson SE;TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team
通讯作者：
TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team
影响因子：
8.2
作者：
Koska, J.;Ortega, E.;Bunt, J. C.;Gasser, A.;Impson, J.;Hanson, R. L.;Forbes, J.;de Courten, B.;Krakoff, J.
通讯作者：
Krakoff, J.